Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites
- 3 May 2018
- journal article
- review article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 63 (7) , 1737-1746
Abstract
The role of nonselective beta-blockers in cirrhotic patients with ascites has been recently questioned; however, definitive evidence in this regard is still lacking.Keywords
This publication has 32 references indexed in Scilit:
- PTU-001 Propanolol at modest dose does not impair survival in patients with cirrhosis and refractory ascitesGut, 2012
- The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1Gut, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Nonselective β-blockers in patients with refractory ascitesNature Reviews Gastroenterology & Hepatology, 2010
- Deleterious Effects of Beta-Blockers on Survival in Patients With Cirrhosis and Refractory Ascites†,‡Hepatology, 2010
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?Journal of Gastroenterology and Hepatology, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trialHepatology, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986